RGEN
NASDAQ · Life Sciences Tools & Services
Repligen Corp
$186.75
+6.04 (+3.34%)
Financial Highlights (FY 2026)
Revenue
742.03M
Net Income
49.14M
Gross Margin
52.6%
Profit Margin
6.6%
Rev Growth
-2.7%
D/E Ratio
0.26
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 52.6% | 52.6% | 33.3% | 33.3% |
| Operating Margin | 7.5% | 6.7% | 6.8% | 6.5% |
| Profit Margin | 6.6% | 6.3% | 7.1% | 6.4% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 742.03M | 762.62M | 4.59B | 4.00B |
| Gross Profit | 390.68M | 401.52M | 1.53B | 1.33B |
| Operating Income | 55.43M | 51.27M | 311.12M | 261.18M |
| Net Income | 49.14M | 45.45M | 325.04M | 256.90M |
| Gross Margin | 52.6% | 52.6% | 33.3% | 33.3% |
| Operating Margin | 7.5% | 6.7% | 6.8% | 6.5% |
| Profit Margin | 6.6% | 6.3% | 7.1% | 6.4% |
| Rev Growth | -2.7% | -2.7% | +1.3% | +8.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 1.03B | 1.03B | 1.77B | 1.35B |
| Total Equity | 4.00B | 4.00B | 3.56B | 3.35B |
| D/E Ratio | 0.26 | 0.26 | 0.50 | 0.40 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 134.60M | 131.42M | 499.02M | 399.89M |
| Free Cash Flow | — | — | 285.62M | 226.18M |